GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, addiction, and even Alzheimer’s. Now, three scientists who played key roles in their invention have won a prestigious Lasker Award for biomedical research.

Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

Together with Habener and others, she proved this theory through lab experiments and human trials, identifying its therapeutic potential.It was only later studies by Habener, Mojsov, and others that revealed GLP-1's ability to slow stomach emptying and its interaction with receptors in the brain,

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker medical awards recognize a trio of scientists without whom Ozempic and other blockbuster weight-loss drugs might not exist.